With $36M series B, Finch goes full speed ahead in microbiome therapy

C. diff
Finch merged with fellow microbiome biotech, Crestovo, in October, picking up the C. difficile treatment CP101 in the process. (Lois S. Wiggs/CDC)

Finch Therapeutics snagged another $36 million in funding, boosting its capital raised to $77 million and enabling it to carry its C. difficile treatment, CP101, through phase 2.

The Somerville, Massachusetts-based startup picked up CP101, what it calls a “full-spectrum microbiota product,” in its October merger with Crestovo. At the time, Crestovo’s pipeline was further ahead, having started a phase 2 trial of CP101 in 240 patients with C. diff infections.

In addition to supporting Finch’s ongoing phase 2 efforts for CP101, the new funding will also advance its earlier-stage pipeline. This includes pushing forward FIN-524, a candidate composed of cultured bacterial strains for treating inflammatory bowel disease.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

Six months before Finch tied the knot with Crestovo, it inked a pact with Takeda that saw the Japanese pharma hand over $10 million for the worldwide rights to FIN-524, as well as the rights to follow-on products for IBD. It was Takeda’s second microbiome deal within a week—the company tapped NuBiyota and its microbiome platform to develop treatments for gastrointestinal diseases.

“We look forward to continued progress in PRISM 3, our ongoing Phase 2 study of CP101, an orally delivered Full-Spectrum Microbiota product being developed for recurrent C. difficile infections,” said Mark Smith, CEO of Finch Therapeutics.

“We are also excited to advance our pipeline of therapeutic candidates into the clinic both through sponsored programs and in collaboration with Takeda and our academic partners as we work to realize the exciting potential of the human microbiome.”